Home

KIYATEC Tagline

KIYATEC is ushering in a new world of cancer diagnostics that
use living cells grown and tested in a more relevant 3D environment.

Clinical Cancer Diagnostics

Cancer DiagnosticsKIYATEC is driving the future of clinical cancer diagnostics to provide more accurate prediction of patient-specific response to cancer treatments.  Placing the patient's own living cancer cells into a more biologically relevant 3D culture environment, KIYATEC cell-based assays can better assist oncologists with improved response data and faster turnaround!

Read More

Services & Partnering

3D Cell CultureKIYATEC’s 3D cell-based models provide physiologically-relevant, efficient and cost-effective platforms for testing both small molecule and biologic drugs in an in vivo-like environment to answer important questions regarding drug efficacy and cellular response. Opportunities also exist for co-clinical trial partnering to apply ex vivo patient selection based on our Drug Response Profiling (DRP) approach.
Read More

Updates

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics
Read More

KIYATEC hires Bryce Chaney as Sr Director of Business Development
Read More

KIYATEC awarded AdvaMed Emerging Growth Company presentation and scholarship
Read More

KIYATEC recognized with spot in NIH "Innovation Zone" at BIO 2014
Read More

KIYATEC appoints Bob Silverman as Board Chairman
Read More

Events

AdvaMed 2014

Emerging Growth Company Presentation
Chicago, IL
Oct 6-8